Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications

Bibliography

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edition. American Psychiatric Association; Washington, DC: 2013
   Google Scholar
• Substance Abuse and Mental Health Services Administration. Results from the 2011 National Survey on drug use and health: summary of national findings. Substance Abuse and Mental Health Services Administration; Rockville, MD: 2012; NSDUH Series H-44, HHS Publication No. (SMA) 12-4713
   Google Scholar
• Substance Abuse and Mental Health Services Administration. Substance abuse and mental health services administration, center for behavioral health statistics and quality. treatment episode data set (TEDS): 2000-2010. National Admissions to Substance Abuse Treatment Services; Rockville, MD: 2012; DASIS Series S-61, HHS Publication No. (SMA) 12-4701
   Google Scholar
• Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. (July 2, 2012). The DAWN Report: Highlights of the 2010 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visits. Rockville, MD
   Google Scholar
• Miller T, Hendrie D. Substance abuse prevention dollars and cents: a cost-benefit analysis. Center for Substance Abuse Prevention, Substance Abuse and Mental Health Services Administration; Rockville, MD: 2008; DHHS Pub. No. (SMA) 07-4298
   Google Scholar
• Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. Lancet 2010;376(9752):1558-65
   PubMed Web of Science ®Google Scholar
• Grace AA, Floresco SB, Goto Y, Lodge DJ. Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends Neurosci 2007;30:220-7
   PubMed Web of Science ®Google Scholar
• Lisman JE, Grace AA. The hippocampal-VTA loop: controlling the entry of information into long-term memory. Neuron 2005;46:703-13
   PubMed Web of Science ®Google Scholar
• Goto Y, Grace AA. Dopaminergic modulation of limbic and cortical drive of nucleus accumbens in goal-directed behavior. Nat Neurosci 2005;8:805-12
   PubMed Web of Science ®Google Scholar
• West AR, Grace AA. Opposite influences of endogenous dopamine D1 and D2 receptor activation on activity states and electrophysiological properties of striatal neurons: studies combining in vivo intracellular recordings and reverse microdialysis. J Neurosci 2002;22:294-304
   PubMed Web of Science ®Google Scholar
• Shohamy D, Adcock RA. Dopamine and adaptive memory. Trends Cogn Sci 2010;14(10):464-72
   PubMed Web of Science ®Google Scholar
• Eichenbaum H. Hippocampus: cognitive processes and neural representations that underlie declarative memory. Neuron 2004;44:109-20
   PubMed Web of Science ®Google Scholar
• Ballard IC, Murty VP, Carter RM, et al. Dorsolateral Prefrontal Cortex Drives Mesolimbic Dopaminergic Regions to Initiate Motivated Behavior. J Neurosci 2011;31:10340-6
   PubMed Web of Science ®Google Scholar
• Carr DB, Sesack SR. Projections from the rat prefrontal cortex to the ventral tegmental area: target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. J Neurosci 2000;20:3864-73
   PubMed Web of Science ®Google Scholar
• Schultz W. Multiple reward signals in the brain. Nat Rev Neurosci 2000;1:199-207
   PubMed Web of Science ®Google Scholar
• Goto Y, Otani S, Grace AA. The Yin and Yang of dopamine release: a new perspective. Neuropharmacology 2007;53:583-7
   PubMed Web of Science ®Google Scholar
• Kringelbach ML. The human orbitofrontal cortex: linking reward to hedonic experience. Nat Rev Neurosci 2005;6:691-702
   PubMed Web of Science ®Google Scholar
• Stern CE, Owen AM, Tracey I, et al. Activity in ventrolateral and mid-dorsolateral prefrontal cortex during nonspatial visual working memory processing: evidence from functional magnetic resonance imaging. Neuroimage 2000;11:392-9
   PubMed Web of Science ®Google Scholar
• Petrides M. Dissociable roles of mid-dorsolateral prefrontal and anterior inferotemporal cortex in visual working memory. J Neurosci 2000;20:7496-503
   PubMed Web of Science ®Google Scholar
• Cohen JD, Braver TS, Brown JW. Computational perspectives on dopamine function in prefrontal cortex. Curr Opin Neurobiol 2002;12:223-9
   PubMed Web of Science ®Google Scholar
• Floresco SB. Prefrontal dopamine and behavioral flexibility: shifting from an “inverted-U” toward a family of functions. Front Neurosci 2013;7:62
   PubMedGoogle Scholar
• Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology 2010;35:217-38
   PubMed Web of Science ®Google Scholar
• Groman SM, Jentsch JD. Cognitive control and the dopamine D-like receptor: a dimensional understanding of addiction. Depress Anxiety 2012;29:295-306
   PubMed Web of Science ®Google Scholar
• Pilcher JE II. Cocaine as an Anaesthetic; its status at the close of the first year of its use. Ann Surg 1886;3:51-66
   PubMedGoogle Scholar
• Rothman RB, Baumann MH, Dersch CM, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001;39:32-41
   PubMed Web of Science ®Google Scholar
• Volkow ND, Fowler JS, Wang GJ, Goldstein RZ. Role of dopamine, the frontal cortex and memory circuits in drug addiction: insight from imaging studies. Neurobiol Learn Mem 2002;78:610-24
   PubMed Web of Science ®Google Scholar
• Haile CN, Mahoney JJ III, Newton TF, De La Garza R II. Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate. Pharmacol Ther 2012;134:260-77
   PubMed Web of Science ®Google Scholar
• Volkow ND, Fowler JS. Addiction, a disease of compulsion and drive: involvement of the orbitofrontal cortex. Cereb Cortex 2000;10:318-25
   PubMed Web of Science ®Google Scholar
• Martinez D, Greene K, Broft A, et al. Lower level of endogenous dopamine in patients with cocaine dependence: findings from PET imaging of D/D receptors following acute dopamine depletion. Am J Psychiatry 2009;166:1170-7
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Fowler JS, et al. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 1997;386:830-3
   PubMed Web of Science ®Google Scholar
• Martinez D, Narendran R, Foltin RW, et al. Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. Am J Psychiatry 2007;164:622-9
   PubMed Web of Science ®Google Scholar
• Narendran R, Lopresti BJ, Martinez D, et al. In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers. Am J Psychiatry 2012;169:55-63
   PubMed Web of Science ®Google Scholar
• Staley JK, Hearn WL, Ruttenber AJ, et al. High affinity cocaine recognition sites on the dopamine transporter are elevated in fatal cocaine overdose victims. J Pharmacol Exp Ther 1994;271:1678-85
   PubMed Web of Science ®Google Scholar
• Bolla K, Ernst M, Kiehl K, et al. Prefrontal cortical dysfunction in abstinent cocaine abusers. J Neuropsychiatry Clin Neurosci 2004;16:456-64
   PubMed Web of Science ®Google Scholar
• London ED, Cascella NG, Wong DF, et al. Cocaine-induced reduction of glucose utilization in human brain. A study using positron emission tomography and [fluorine 18]- fluorodeoxyglucose. Arch Gen Psychiatry 1990;47:567-74
   PubMed Web of Science ®Google Scholar
• Fernandez-Serrano MJ, Perales JC, Moreno-Lopez L, et al. Neuropsychological profiling of impulsivity and compulsivity in cocaine dependent individuals. Psychopharmacology (Berl) 2012;219:673-83
   PubMed Web of Science ®Google Scholar
• Martinez D, Carpenter KM, Liu F, et al. Imaging dopamine transmission in cocaine dependence: link between neurochemistry and response to treatment. Am J Psychiatry 2011;168:634-41
   PubMed Web of Science ®Google Scholar
• Wang GJ, Smith L, Volkow ND, et al. Decreased dopamine activity predicts relapse in methamphetamine abusers. Mol Psychiatry 2012;17:918-25
   PubMed Web of Science ®Google Scholar
• Sulzer D. How addictive drugs disrupt presynaptic dopamine neurotransmission. Neuron 2011;69:628-49
   PubMed Web of Science ®Google Scholar
• Drevets WC, Gautier C, Price JC, et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 2001;49:81-96
   PubMed Web of Science ®Google Scholar
• Chang L, Alicata D, Ernst T, Volkow N. Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction 2007;102(Suppl 1):16-32
   PubMed Web of Science ®Google Scholar
• Volkow ND, Chang L, Wang GJ, et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 2001;21:9414-18
   PubMed Web of Science ®Google Scholar
• London ED, Simon SL, Berman SM, et al. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry 2004;61:73-84
   PubMed Web of Science ®Google Scholar
• Nestor LJ, Ghahremani DG, Monterosso J, London ED. Prefrontal hypoactivation during cognitive control in early abstinent methamphetamine-dependent subjects. Psychiatry Res 2011;194:287-95
   PubMed Web of Science ®Google Scholar
• Volkow ND, Chang L, Wang GJ, et al. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry 2001;158:2015-21
   PubMed Web of Science ®Google Scholar
• Cruickshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine. Addiction 2009;104:1085-99
   PubMed Web of Science ®Google Scholar
• McCann UD, Kuwabara H, Kumar A, et al. Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse 2008;62:91-100
   PubMed Web of Science ®Google Scholar
• Lee B, London ED, Poldrack RA, et al. Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J Neurosci 2009;29:14734-40
   PubMed Web of Science ®Google Scholar
• Devane WA, Dysarz FA, Johnson MR, et al. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988;34:605-13
   PubMed Web of Science ®Google Scholar
• Solinas M, Goldberg SR, Piomelli D. The endocannabinoid system in brain reward processes. Br J Pharmacol 2008;154:369-83
   PubMed Web of Science ®Google Scholar
• Fitzgerald ML, Shobin E, Pickel VM. Cannabinoid modulation of the dopaminergic circuitry: implications for limbic and striatal output. Prog Neuropsychopharmacol Biol Psychiatry 2012;38:21-9
   PubMed Web of Science ®Google Scholar
• Bossong MG, van Berckel BN, Boellaard R, et al. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009;34:759-66
   PubMed Web of Science ®Google Scholar
• Diana M, Melis M, Muntoni AL, et al. Mesolimbic dopaminergic decline after cannabinoid withdrawal. Proc Natl Acad Sci USA 1998;95(17):10269-73
   PubMed Web of Science ®Google Scholar
• Tanda G, Loddo P, Di Chiara dG. Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol. Eur J Pharmacol 1999;376:23-6
   PubMed Web of Science ®Google Scholar
• Sevy S, Smith GS, Ma Y, et al. Cerebral glucose metabolism and D2/D3 receptor availability in young adults with cannabis dependence measured with positron emission tomography. Psychopharmacology (Berl) 2008;197:549-56
   PubMed Web of Science ®Google Scholar
• Bloomfield MA, Morgan CJ, Egerton A, et al. Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol Psychiatry 2013; pii: S0006-3223(13)00502-7
   Web of Science ®Google Scholar
• Albrecht DS, Skosnik PD, Vollmer JM, et al. Striatal D/D receptor availability is inversely correlated with cannabis consumption in chronic marijuana users. Drug Alcohol Depend 2013;128:52-7
   PubMed Web of Science ®Google Scholar
• Urban NB, Slifstein M, Thompson JL, et al. Dopamine release in chronic cannabis users: a [11c]raclopride positron emission tomography study. Biol Psychiatry 2012;71:677-83
   PubMed Web of Science ®Google Scholar
• Villares J. Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain. Neuroscience 2007;145:323-34
   PubMed Web of Science ®Google Scholar
• Hirvonen J, Goodwin RS, Li CT, et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry 2012;17:642-9
   PubMed Web of Science ®Google Scholar
• Lorenzetti V, Lubman DI, Whittle S, et al. Structural MRI findings in long-term cannabis users: what do we know? Subst Use Misuse 2010;45:1787-808
   PubMed Web of Science ®Google Scholar
• Fischman MW, Foltin RW. Utility of subjective-effects measurements in assessing abuse liability of drugs in humans. Br J Addict 1991;86:1563-70
   PubMedGoogle Scholar
• Kosten TR, George TP, Kosten TA. The potential of dopamine agonists in drug addiction. Expert Opin Investig Drugs 2002;11:491-9
   PubMed Web of Science ®Google Scholar
• Herin DV, Rush CR, Grabowski J. Agonist-like pharmacotherapy for stimulant dependence: preclinical, human laboratory, and clinical studies. Ann N Y Acad Sci 2010;1187:76-100
   PubMed Web of Science ®Google Scholar
• Grabowski J, Shearer J, Merrill J, et al. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav 2004;29:1439-64
   PubMed Web of Science ®Google Scholar
• Alvarez Y, Perez-Mana C, Torrens M, et al. Antipsychotic drugs in cocaine dependence: a systematic review and meta-analysis. J Subst Abuse Treat 2013;45:1-10
   PubMed Web of Science ®Google Scholar
• Ohuoha DC, Maxwell JA, Thomson LE III, et al. Effect of dopamine receptor antagonists on cocaine subjective effects: a naturalistic case study. J Subst Abuse Treat 1997;14:249-58
   PubMed Web of Science ®Google Scholar
• Amato L, Minozzi S, Pani PP, et al. Dopamine agonists for the treatment of cocaine dependence. Cochrane Database Syst Rev 2011;12:CD003352
   PubMedGoogle Scholar
• Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 2009;301:1148-54
   PubMed Web of Science ®Google Scholar
• Vosburg SK, Hart CL, Haney M, et al. Modafinil does not serve as a reinforcer in cocaine abusers. Drug Alcohol Depend 2010;106:233-6
   PubMed Web of Science ®Google Scholar
• Goudriaan AE, Veltman DJ, van den Brink W, et al. Neurophysiological effects of modafinil on cue-exposure in cocaine dependence: a randomized placebo-controlled cross-over study using pharmacological fMRI. Addict Behav 2013;38:1509-17
   PubMed Web of Science ®Google Scholar
• Kalechstein AD, Mahoney JJ III, Yoon JH, et al. Modafinil, but not escitalopram, improves working memory and sustained attention in long-term, high-dose cocaine users. Neuropharmacology 2013;64:472-8
   PubMed Web of Science ®Google Scholar
• Dackis CA, Kampman KM, Lynch KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005;30:205-11
   PubMed Web of Science ®Google Scholar
• Dackis CA, Lynch KG, Yu E, et al. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend 2003;70:29-37
   PubMed Web of Science ®Google Scholar
• Malcolm R, Swayngim K, Donovan JL, et al. Modafinil and cocaine interactions. Am J Drug Alcohol Abuse 2006;32:577-87
   PubMed Web of Science ®Google Scholar
• Hart CL, Haney M, Vosburg SK, et al. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 2008;33:761-8
   PubMed Web of Science ®Google Scholar
• Anderson AL, Li SH, Biswas K, et al. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend 2009;104:133-9
   PubMed Web of Science ®Google Scholar
• Dackis CA, Kampman KM, Lynch KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. J Subst Abuse Treat 2012;43:303-12
   PubMed Web of Science ®Google Scholar
• Schmitz JM, Rathnayaka N, Green CE, et al. Combination of Modafinil and d-amphetamine for the Treatment of Cocaine Dependence: a Preliminary Investigation. Front Psychiatry 2012;3:77
   PubMedGoogle Scholar
• Dwoskin LP, Rauhut AS, King-Pospisil KA, et al. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 2006;12:178-207
   PubMedGoogle Scholar
• Oliveto A, McCance-Katz FE, Singha A, et al. Effects of cocaine prior to and during bupropion maintenance in cocaine-abusing volunteers. Drug Alcohol Depend 2001;63:155-67
   PubMed Web of Science ®Google Scholar
• Stoops WW, Lile JA, Glaser PE, et al. Influence of acute bupropion pre-treatment on the effects of intranasal cocaine. Addiction 2012;107:1140-7
   PubMed Web of Science ®Google Scholar
• Margolin A, Kosten T, Petrakis I, et al. Bupropion reduces cocaine abuse in methadone-maintained patients. Arch Gen Psychiatry 1991;48:87
   PubMed Web of Science ®Google Scholar
• Margolin A, Kosten TR, Avants SK, et al. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend 1995;40:125-31
   PubMed Web of Science ®Google Scholar
• Poling J, Oliveto A, Petry N, et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry 2006;63:219-28
   PubMed Web of Science ®Google Scholar
• Shoptaw S, Heinzerling KG, Rotheram-Fuller E, et al. Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence. J Addict Dis 2008;27:13-23
   PubMed Web of Science ®Google Scholar
• Montoya ID, Preston KL, Rothman R, Gorelick DA. Open-label pilot study of bupropion plus bromocriptine for treatment of cocaine dependence. Am J Drug Alcohol Abuse 2002;28:189-96
   PubMed Web of Science ®Google Scholar
• Maldonado R. Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate. Expert Opin Drug Metab Toxicol 2013;9:1001-14
   PubMed Web of Science ®Google Scholar
• Lile JA, Wang Z, Woolverton WL, et al. The reinforcing efficacy of psychostimulants in rhesus monkeys: the role of pharmacokinetics and pharmacodynamics. J Pharmacol Exp Ther 2003;307:356-66
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Fowler JS, et al. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57:1410-15
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Tomasi D, et al. Methylphenidate attenuates limbic brain inhibition after cocaine-cues exposure in cocaine abusers. PLoS One 2010;5:e11509
   PubMed Web of Science ®Google Scholar
• Goldstein RZ, Volkow ND. Oral methylphenidate normalizes cingulate activity and decreases impulsivity in cocaine addiction during an emotionally salient cognitive task. Neuropsychopharmacology 2011;36:366-7
   PubMed Web of Science ®Google Scholar
• Collins SL, Levin FR, Foltin RW, et al. Response to cocaine, alone and in combination with methylphenidate, in cocaine abusers with ADHD. Drug Alcohol Depend 2006;82:158-67
   PubMed Web of Science ®Google Scholar
• Winhusen T, Somoza E, Singal BM, et al. Methylphenidate and cocaine: a placebo-controlled drug interaction study. Pharmacol Biochem Behav 2006;85:29-38
   PubMed Web of Science ®Google Scholar
• Grabowski J, Roache JD, Schmitz JM, et al. Replacement medication for cocaine dependence: methylphenidate. J Clin Psychopharmacol 1997;17:485-8
   PubMed Web of Science ®Google Scholar
• Schubiner H, Saules KK, Arfken CL, et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 2002;10:286-94
   PubMed Web of Science ®Google Scholar
• Somoza EC, Winhusen TM, Bridge TP, et al. An open-label pilot study of methylphenidate in the treatment of cocaine dependent patients with adult attention deficit/hyperactivity disorder. J Addict Dis 2004;23:77-92
   PubMed Web of Science ®Google Scholar
• Levin FR, Evans SM, Brooks DJ, et al. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend 2007;87:20-9
   PubMed Web of Science ®Google Scholar
• Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol 2009;23:419-27
   PubMed Web of Science ®Google Scholar
• Rush CR, Stoops WW, Hays LR. Cocaine effects during D-amphetamine maintenance: a human laboratory analysis of safety, tolerability and efficacy. Drug Alcohol Depend 2009;99:261-71
   PubMed Web of Science ®Google Scholar
• Rush CR, Stoops WW, Sevak RJ, Hays LR. Cocaine choice in humans during D-amphetamine maintenance. J Clin Psychopharmacol 2010;30:152-9
   PubMed Web of Science ®Google Scholar
• Grabowski J, Rhoades H, Schmitz J, et al. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J Clin Psychopharmacol 2001;21:522-6
   PubMed Web of Science ®Google Scholar
• Grabowski J, Rhoades H, Stotts A, et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology 2004;29:969-81
   PubMed Web of Science ®Google Scholar
• Mariani JJ, Pavlicova M, Bisaga A, et al. Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial. Biol Psychiatry 2012;72:950-6
   PubMed Web of Science ®Google Scholar
• Mooney ME, Herin DV, Schmitz JM, et al. Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 2009;101:34-41
   PubMed Web of Science ®Google Scholar
• Haberny KA, Walsh SL, Ginn DH, et al. Absence of acute cocaine interactions with the MAO-B inhibitor selegiline. Drug Alcohol Depend 1995;39:55-62
   PubMed Web of Science ®Google Scholar
• Newton TF, Kalechstein A, Beckson M, et al. Effects of selegiline pretreatment on response to experimental cocaine administration. Psychiatry Res 1999;87:101-6
   PubMed Web of Science ®Google Scholar
• Harris DS, Everhart T, Jacob P III, et al. A phase 1 trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion. BMC Clin Pharmacol 2009;9:13
   PubMedGoogle Scholar
• Elkashef A, Fudala PJ, Gorgon L, et al. Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence. Drug Alcohol Depend 2006;85:191-7
   PubMed Web of Science ®Google Scholar
• Mooney ME, Schmitz JM, Moeller FG, et al. Safety, tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: two double-blind, randomized, clinical trials. Drug Alcohol Depend 2007;88:214-23
   PubMed Web of Science ®Google Scholar
• Schmitz JM, Mooney ME, Moeller FG, et al. Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform. Drug Alcohol Depend 2008;94:142-50
   PubMed Web of Science ®Google Scholar
• Schmitz JM, Lindsay JA, Stotts AL, et al. Contingency management and levodopa-carbidopa for cocaine treatment: a comparison of three behavioral targets. Exp Clin Psychopharmacol 2010;18:238-44
   PubMed Web of Science ®Google Scholar
• De La Garza R II, Zorick T, London ED, et al. Newton, evaluation of modafinil effects on cardiovascular, subjective, and reinforcing effects of methamphetamine in methamphetamine-dependent volunteers. Drug Alcohol Depend 2010;106:173-80
   PubMed Web of Science ®Google Scholar
• McElhiney MC, Rabkin JG, Rabkin R, Nunes EV. Provigil (modafinil) plus cognitive behavioral therapy for methamphetamine use in HIV+ gay men: a pilot study. Am J Drug Alcohol Abuse 2009;35:34-7
   PubMed Web of Science ®Google Scholar
• McGaugh J, Mancino MJ, Feldman Z, et al. Open-label pilot study of modafinil for methamphetamine dependence. J Clin Psychopharmacol 2009;29:488-91
   PubMed Web of Science ®Google Scholar
• Shearer J, Darke S, Rodgers C, et al. A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction 2009;104:224-33
   PubMed Web of Science ®Google Scholar
• Anderson AL, Li SH, Biswas K, et al. Modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend 2012;120:135-41
   PubMed Web of Science ®Google Scholar
• Newton TF, Roache JD, De La Garza R II, et al. Safety of intravenous methamphetamine administration during treatment with bupropion. Psychopharmacology (Berl) 2005;182:426-35
   PubMed Web of Science ®Google Scholar
• Newton TF, Roache JD, De La Garza R II, et al. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 2006;31:1537-44
   PubMed Web of Science ®Google Scholar
• Shoptaw S, Heinzerling KG, Rotheram-Fuller E, et al. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend 2008;96:222-32
   PubMed Web of Science ®Google Scholar
• Elkashef AM, Rawson RA, Anderson AL, et al. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology 2008;33:1162-70
   PubMed Web of Science ®Google Scholar
• Laqueille X, Dervaux A, El Omari F, et al. Methylphenidate effective in treating amphetamine abusers with no other psychiatric disorder. Eur Psychiatry 2005;20:456-7
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Kuoppasalmi K, Fohr J, et al. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatry 2007;164:160-2
   PubMed Web of Science ®Google Scholar
• Miles SW, Sheridan J, Russell B, et al. Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double-blind, placebo-controlled trial. Addiction 2013;108(7):1279-86
   PubMed Web of Science ®Google Scholar
• Shearer J, Wodak A, Mattick RP, et al. Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence. Addiction 2001;96:1289-96
   PubMed Web of Science ®Google Scholar
• Longo M, Wickes W, Smout M, et al. Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. Addiction 2010;105:146-54
   PubMed Web of Science ®Google Scholar
• Galloway GP, Buscemi R, Coyle JR, et al. A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction. Clin Pharmacol Ther 2011;89:276-82
   PubMed Web of Science ®Google Scholar
• Sugarman DE, Poling J, Sofuoglu M. The safety of modafinil in combination with oral 9-tetrahydrocannabinol in humans. Pharmacol Biochem Behav 2011;98:94-100
   PubMed Web of Science ®Google Scholar
• Haney M, Ward AS, Comer SD, et al. Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology (Berl) 2001;155:171-9
   PubMed Web of Science ®Google Scholar
• Carpenter KM, McDowell D, Brooks DJ, et al. A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. Am J Addict 2009;18:53-64
   PubMed Web of Science ®Google Scholar
• Lile JA, Kelly TH, Hays LR. The reinforcing, self-reported performance and physiological effects of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in cannabis users. Behav Pharmacol 2010;21:29-38
   PubMed Web of Science ®Google Scholar
• Haney M. Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls. Addict Biol 2009;14:9-21
   PubMed Web of Science ®Google Scholar
• Kamon J, Budney A, Stanger C. A contingency management intervention for adolescent marijuana abuse and conduct problems. J Am Acad Child Adolesc Psychiatry 2005;44:513-21
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Chiu WT, Sampson N, et al. Toward a global view of alcohol, tobacco, cannabis, and cocaine use: findings from the WHO World Mental Health Surveys. PLoS Med 2008;5:e141
   PubMed Web of Science ®Google Scholar
• Winters KC, Lee CY. Likelihood of developing an alcohol and cannabis use disorder during youth: association with recent use and age. Drug Alcohol Depend 2008;92(1-3):239-47
   PubMed Web of Science ®Google Scholar
• Wagner FA, Anthony JC. From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol. Neuropsychopharmacology 2002;26:479-88
   PubMed Web of Science ®Google Scholar
• Vandrey R, Haney M. Pharmacotherapy for cannabis dependence: how close are we? CNS Drugs 2009;23:543-53
   PubMed Web of Science ®Google Scholar
• Copeland J, Swift W, Roffman R, et al. A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. J Subst Abuse Treat 2001;21:55-64
   PubMed Web of Science ®Google Scholar
• Stephens RS, Roffman RA, Curtin L. Comparison of extended versus brief treatments for marijuana use. J Consult Clin Psychol 2000;68:898-908
   PubMed Web of Science ®Google Scholar
• Zhang XY, Kosten TA. Prazosin, an alpha-1 adrenergic antagonist, reduces cocaine-induced reinstatement of drug-seeking. Biol Psychiatry 2005;57:1202-4
   PubMed Web of Science ®Google Scholar
• Hamilton JD, Nguyen QX, Gerber RM, et al. Olanzapine in cocaine dependence: a double-blind, placebo-controlled trial. Am J Addict 2009;18:48-52
   PubMed Web of Science ®Google Scholar
• Elkashef A, Vocci F. Biological markers of cocaine addiction: implications for medications development. Addict Biol 2003;8:123-39
   PubMed Web of Science ®Google Scholar
• Drouin C, Blanc G, Trovero F, et al. Cortical alpha 1-adrenergic regulation of acute and sensitized morphine locomotor effects. Neuroreport 2001;12:3483-6
   PubMed Web of Science ®Google Scholar
• Drouin C, Blanc G, Villegier AS, et al. Critical role of alpha1-adrenergic receptors in acute and sensitized locomotor effects of D-amphetamine, cocaine, and GBR 12783: influence of preexposure conditions and pharmacological characteristics. Synapse 2002;43:51-61
   PubMed Web of Science ®Google Scholar
• Drouin C, Darracq L, Trovero F, et al. Alpha 1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. J Neurosci 2002;22:2873-84
   PubMed Web of Science ®Google Scholar
• Haile C, Hao Y, O'Malley P, et al. The alpha 1 antagonist doxazosin alters the behavioral effects of cocaine in rats. Brain Sci 2012;2:619-33
   Google Scholar
• Newton TF, De La Garza R II, Brown G, et al. Noradrenergic alpha 1 receptor antagonist treatment attenuates positive subjective effects of cocaine in humans: a randomized trial. PLoS One 2012;7:e30854
   PubMed Web of Science ®Google Scholar
• Shorter D, Lindsay JA, Kosten TR. The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: a pilot study. Drug Alcohol Depend 2013;131(1-2):66-70
   PubMed Web of Science ®Google Scholar
• Czoty PW, Ginsburg BC, Howell LL. Serotonergic attenuation of the reinforcing and neurochemical effects of cocaine in squirrel monkeys. J Pharmacol Exp Ther 2002;300:831-7
   PubMed Web of Science ®Google Scholar
• Volkow ND, Fowler JS, Wang GJ. The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. Neuropharmacology 2004;47:3-13
   PubMed Web of Science ®Google Scholar